We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Iron Mountain
IRM
$37.4B
| $168K | ﹤0.01% |
5,316
+697
| +15% | +$22.9K |
|
1077
Goodyear
GT
$2.12B
| $167K | ﹤0.01% |
10,793
| – | – |
|
|
INVX
1078
Innovex International
INVX
$1.79B
| $167K | ﹤0.01% |
3,570
+148
| +4% | +$6.78K |
|
1079
Broadridge
BR
$18.3B
| $166K | ﹤0.01% |
1,349
-1,934
| -59% | -$236K |
|
|
DCM
1080
DELISTED
NTT DOCOMO, Inc.
DCM
| $166K | ﹤0.01% |
5,974
+2,178
| +57% | +$60.5K |
|
1081
Enphase Energy
ENPH
$4.79B
| $165K | ﹤0.01% |
6,321
+296
| +5% | +$6.74K |
|
1082
Invesco KBW Bank ETF
KBWB
$6.9B
| $165K | ﹤0.01% |
+2,850
| New | +$157K |
|
1083
Cass Information Systems
CASS
$720M
| $164K | ﹤0.01% |
2,842
| – | – |
|
|
KRTX
1084
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $164K | ﹤0.01% |
+2,190
| New | +$95.9K |
|
1085
Scansource
SCSC
$1.16B
| $162K | ﹤0.01% |
4,390
+139
| +3% | +$4.72K |
|
1086
Sumitomo Mitsui Financial
SMFG
$163B
| $162K | ﹤0.01% |
21,975
+4,438
| +25% | +$31.9K |
|
1087
Sensient Technologies
SXT
$5.3B
| $161K | ﹤0.01% |
2,445
+51
| +2% | +$3.27K |
|
1088
CEVA Inc
CEVA
$883M
| $160K | ﹤0.01% |
5,970
| – | – |
|
1089
Mine Safety
MSA
$6.94B
| $160K | ﹤0.01% |
1,269
-136
| -10% | -$16.4K |
|
|
NAB
1090
DELISTED
NATL AUSTRALIA BK LTD ADS5
NAB
| $159K | ﹤0.01% |
18,474
-540
| -3% | -$4.65K |
|
1091
Novanta
NOVT
$5.04B
| $158K | ﹤0.01% |
1,795
+275
| +18% | +$23.7K |
|
1092
Stepan Co
SCL
$1.32B
| $157K | ﹤0.01% |
1,535
+31
| +2% | +$3.02K |
|
1093
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $157K | ﹤0.01% |
1,663
| – | – |
|
|
XLNX
1094
DELISTED
Xilinx Inc
XLNX
| $157K | ﹤0.01% |
1,620
-70,239
| -98% | -$6.6M |
|
1095
KB Financial Group
KB
$40.6B
| $156K | ﹤0.01% |
3,774
+405
| +12% | +$15.5K |
|
|
PCH
1096
DELISTED
PotlatchDeltic
PCH
| $156K | ﹤0.01% |
3,606
| – | – |
|
|
INXN
1097
DELISTED
Interxion Holding N.V.
INXN
| $156K | ﹤0.01% |
1,870
-4,150
| -69% | -$347K |
|
1098
Artisan Partners
APAM
$2.9B
| $155K | ﹤0.01% |
4,812
| – | – |
|
1099
Compugen
CGEN
$214M
| $154K | ﹤0.01% |
26,000
| – | – |
|
1100
CRISPR Therapeutics
CRSP
$4.68B
| $154K | ﹤0.01% |
2,550
-350
| -12% | -$19.1K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.